| HOME >> BIOLOGY >> TECHNOLOGY |
lease..................... 39 16
Deferred
revenue..................................... 228 228
Accrued severance
pay................................. 381 324
Total Long-term
Liabilities........................... 648 568
commitments and contingent liabilities
SHAREHOLDERS' EQUITY:
Share
capital:...................................... 27 27
Additional paid-in
capital............................... 59,503 58,984
Other comprehensive
income............................ (3) 86
Deferred stock-based
compensation....................... - -
Deficit accumulated during the development
stage............ (43,067) (35,492)
Total shareholders'
equity........................... 16,460 23,605
Total liabilities and shareholders'
equity............... $ 18,641 $ 26,038
---------------------------------
(1) American Cancer Society website, 2008 (2) Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung
and pleural tumours. 3rd ed. Berlin: Springer-Verlag, 1999.
Contact: Investors
Joshua Gordon, M.D.
T: +1-201-946-0561
E: investors@rosettagenomics.com
Media
Ron Kamienchick
T: +1-646-509-1893
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |